Heim500660 • BOM
add
GlaxoSmithKline Pharmaceuticals Ltd
Við síðustu lokun
1.990,85 ₹
Dagbil
1.984,00 ₹ - 2.016,95 ₹
Árabil
1.825,05 ₹ - 3.087,95 ₹
Markaðsvirði
336,77 ma. INR
Meðalmagn
3,26 þ.
V/H-hlutf.
50,24
A/V-hlutfall
1,61%
Aðalkauphöll
NSE
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (INR) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 10,11 ma. | 5,62% |
Rekstrarkostnaður | 3,21 ma. | -2,94% |
Nettótekjur | 2,52 ma. | 16,09% |
Hagnaðarhlutfall | 24,98 | 9,90% |
Hagnaður á hvern hlut | — | — |
EBITDA | 3,21 ma. | 11,39% |
Virkt skatthlutfall | 26,56% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (INR) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 21,11 ma. | 31,49% |
Heildareignir | 37,46 ma. | 14,55% |
Heildarskuldir | 20,73 ma. | 19,80% |
Eigið fé alls | 16,73 ma. | — |
Útistandandi hlutabréf | 172,12 m. | — |
Eiginfjárgengi | 20,49 | — |
Arðsemi eigna | — | — |
Ávöxtun eigin fjár | 43,75% | — |
Peningaflæði
Breyting á handbæru fé
| (INR) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 2,52 ma. | 16,09% |
Handbært fé frá rekstri | — | — |
Reiðufé frá fjárfestingum | — | — |
Reiðufé frá fjármögnun | — | — |
Breyting á handbæru fé | — | — |
Frjálst peningaflæði | — | — |
Um
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
Stofnsett
13. nóv. 1924
Vefsvæði
Starfsfólk
3.211
